Dark

Check out our Dark Pool Levels

DBTX
Decibel Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Sep 22, 2023

4.91USD-0.808%(-0.04)1,261,176

Pre-market

0.00USD-100.000%(-4.95)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

07:00AM EST Decibel Therapeutics to Present at the 45th Annual Association for GlobeNewswire Inc

Jan 4, 2022

07:00AM EST Decibel Therapeutics to Present at the H.C. Wainwright BioConnect GlobeNewswire Inc

Dec 6, 2021

07:30AM EST Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointments of Alison Finger, MBA and Saraswathy (Sara) Nochur, Ph.D. to its Board of Directors. GlobeNewswire Inc

Dec 2, 2021

08:44AM EST JonesTrading Initiates Coverage On Decibel Therapeutics with Buy Rating, Announces Price Target of $25 Benzinga

Nov 22, 2021

10:34AM EST Regeneron Extends Hearing Loss Gene Therapy pact With Decibel Benzinga

07:38AM EST Decibel Therapeutics to Receive $10M from Regeneron for Extension of Research Term Under Strategic Collaboration for Hearing Loss Benzinga

07:30AM EST -- Collaboration gene therapy product candidate, DB-OTO, on track to enter clinical testing in 2022; two additional gene therapy programs for congenital, monogenic forms of hearing loss in development under the collaboration -- Decibel to receive $10 million extension payment from Regeneron GlobeNewswire Inc

Nov 15, 2021

10:48AM EST HC Wainwright & Co. Initiates Coverage On Decibel Therapeutics with Buy Rating, Announces Price Target of $23 Benzinga

Nov 10, 2021

12:33PM EST SVB Leerink Maintains Outperform on Decibel Therapeutics, Lowers Price Target to $14 Benzinga

07:44AM EST Decibel Therapeutics Q3 Net Loss $16.399M vs Net Loss $7.111M In Same Qtr. Last Year Benzinga

07:43AM EST Decibel Therapeutics Q3 Net Loss $16.4 Mln Vs Loss $7.1 Mln Last Year RTTNews

07:30AM EST - Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss GlobeNewswire Inc

Nov 8, 2021

07:00AM EST Decibel Therapeutics to Present at the Barclays Gene Editing & GlobeNewswire Inc

Oct 22, 2021

05:37AM EDT Baird Initiates Coverage On Decibel Therapeutics with Outperform Rating, Announces Price Target of $21 Benzinga

Oct 20, 2021

07:35AM EDT Decibel Therapeutics to Present at the Jefferies Gene Therapy/Editing Summit Benzinga

07:30AM EDT Decibel Therapeutics to Present at the Jefferies Gene GlobeNewswire Inc

Sep 30, 2021

05:47PM EDT Decibel Therapeutics Announces Publication Of Foundational Study Of Noise-related Inner Ear Damage Benzinga

05:42PM EDT Decibel Therapeutics Announces Publication of Foundational Study GlobeNewswire Inc

Sep 9, 2021

07:31AM EDT Decibel Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designations For DB-OTO For The Treatment Of Otoferlin-Related Congenital Hearing Loss Benzinga

07:30AM EDT Decibel Therapeutics Receives Orphan Drug and Rare Pediatric GlobeNewswire Inc

Sep 2, 2021

07:30AM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the following upcoming virtual investor conferences in September. GlobeNewswire Inc

Aug 18, 2021

07:30AM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary. GlobeNewswire Inc

Aug 10, 2021

07:40AM EDT Decibel Therapeutics Q2 Cash Position $184.6M Benzinga

07:30AM EDT - Bolstered Board of Directors and Scientific Advisory Board with key appointments - GlobeNewswire Inc

Jun 2, 2021

08:48AM EDT Decibel Therapeutics Appoints William Carson As Chairman Of Board RTTNews

08:30AM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M.D., as Chairman of the Board of Directors. GlobeNewswire Inc

May 24, 2021

04:15PM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene therapy, cochlear development and molecular genetics to its Scientific Advisory Board (SAB). GlobeNewswire Inc

May 19, 2021

08:00AM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 7:00 am ET. GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

06:45AM EDT SVB Leerink Maintains Outperform on Decibel Therapeutics, Lowers Price Target to $18 Benzinga

May 13, 2021

05:41PM EDT Decibel Therapeutics Issues Guidance Says Based On Its Current Operating And Development Plans, Decibel Believes That Its Existing Cash, Cash Equivalents And Available-For-Sale Securities Will Fund Its Pipeline Programs And Operating Expenses Into 2024 Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 28, 2021

08:00AM EDT Decibel Therapeutics to Present at theAmerican Society GlobeNewswire Inc

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Apr 8, 2021

08:00AM EDT Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 pm ET. GlobeNewswire Inc

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 29, 2021

04:05PM EDT -Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- GlobeNewswire Inc

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 22, 2021

08:22AM EDT Decibel Therapeutics Added To Russell 2000 Index Benzinga

08:00AM EDT Decibel Therapeutics (Nasdaq: DBTX) (Decibel), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000 Index, as part of the indexs quarterly initial public offering (IPO) additions. GlobeNewswire Inc

Mar 9, 2021

10:45AM EST Citigroup Initiates Coverage On Decibel Therapeutics with Buy Rating, Announces Price Target of $29 Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021 Benzinga

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

09:16AM EST BMO Capital Initiates Coverage On Decibel Therapeutics with Outperform Rating, Announces Price Target of $30 Benzinga

09:15AM EST Barclays Initiates Coverage On Decibel Therapeutics with Overweight Rating, Announces Price Target of $30 Benzinga

09:15AM EST SVB Leerink Initiates Coverage On Decibel Therapeutics with Outperform Rating, Announces Price Target of $26 Benzinga

Mar 4, 2021

08:01AM EST Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. ET. GlobeNewswire Inc

Mar 2, 2021

06:16AM EST OrbiMed Advisors Reported 16.7% Stake in Decibel Therapeutics in 13D Filing Benzinga

Feb 24, 2021

01:52PM EST Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies Benzinga

07:05AM EST Decibel Therapeutics Says Presented Preclinical Data Supporting Co's Gene Therapy Product Candidate DB-OTO Benzinga

07:00AM EST Decibel Therapeutics Presents Promising Preclinical Findings on GlobeNewswire Inc

Feb 20, 2021

02:17PM EST The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More Benzinga

Feb 19, 2021

07:00AM EST Decibel Therapeutics to Present at the 44th Annual Association for GlobeNewswire Inc

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 12, 2021

11:58AM EST Decibel Therapeutics Shares Open For Trade At $21.20; IPO Priced At $18/Share Benzinga

10:35AM EST Decibel Therapeutics Shares Will Open For Quote At 11:00 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST, IPO Priced At $18/Share Benzinga

10:35AM EST Correction: Decibel Therapeutics Shares Will Open For Quote At 11:00 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST, IPO Priced At $18/Share Benzinga

10:06AM EST Decibel Therapeutics Shares Will Open For Trade At 11:00 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST, IPO Priced At $18/Share Benzinga

Feb 11, 2021

09:51PM EST Decibel Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share